Gilead Sciences (GILD) Dividends Paid - Common (2009 - 2026)
Gilead Sciences' (GILD) quarterly Dividends Paid - Common came in at $1.0 billion in Q2 2026, up 3.41% on a YoY basis from $997.0 million in Q2 2025, and down 0.87% quarter-over-quarter from $1.0 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Dividends Paid - Common (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Dividends Paid - Common for 13 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Dividends Paid - Common rose 3.41% year-over-year to $1.0 billion; the trailing twelve-month figure through Jun 2026 stood at $4.1 billion (up 2.6% YoY), and the FY2025 full-year result was $4.0 billion, up 2.17% from the prior year.
- Dividends Paid - Common slipped to $1.0 billion in Q2 2026 per GILD's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Dividends Paid - Common topped out at $1.0 billion in Q1 2026 and bottomed at $928.0 million in Q4 2022.
- Historically, Dividends Paid - Common has averaged $974.8 million across 5 years, with a median of $975.0 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Dividends Paid - Common advanced 1.84% in 2025, then gained 3.41% in 2026.
- Over 5 years, Dividends Paid - Common stood at $928.0 million in 2022, then advanced by 2.16% to $948.0 million in 2023, then advanced by 2.64% to $973.0 million in 2024, then increased by 2.16% to $994.0 million in 2025, then rose by 3.72% to $1.0 billion in 2026.
- According to Business Quant data, Dividends Paid - Common over the past three periods registered $1.0 billion, $1.0 billion, and $994.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends Paid - Common (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.36 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 1.03 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 96.80 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 1.04 Bn |
| Dec 31, 2025 | 994.00 Mn |
| Sep 30, 2025 | 995.00 Mn |
| Jun 30, 2025 | 997.00 Mn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 973.00 Mn |
| Sep 30, 2024 | 977.00 Mn |
| Jun 30, 2024 | 978.00 Mn |
| Mar 31, 2024 | 990.00 Mn |
| Dec 31, 2023 | 948.00 Mn |
| Sep 30, 2023 | 953.00 Mn |
| Jun 30, 2023 | 954.00 Mn |
| Mar 31, 2023 | 969.00 Mn |
| Dec 31, 2022 | 928.00 Mn |
| Sep 30, 2022 | 933.00 Mn |
| Jun 30, 2022 | 932.00 Mn |
| Mar 31, 2022 | 945.00 Mn |
| Dec 31, 2021 | 904.00 Mn |
| Sep 30, 2021 | 905.00 Mn |